MP69-13 PATIENT REPORTED HEALTH AND QUALITY OF LIFE AFTER NEOADJUVANT CHEMOTHERAPY AND CYSTECTOMY: RESULTS FROM BLADDER CANCER OUTCOMES AND IMPACT STUDY

Abstract

You have accessJournal of UrologyGeneral & Epidemiological Trends & Socioeconomics: Practice Patterns, Quality of Life and Shared Decision Making III1 Apr 2017MP69-13 PATIENT REPORTED HEALTH AND QUALITY OF LIFE AFTER NEOADJUVANT CHEMOTHERAPY AND CYSTECTOMY: RESULTS FROM BLADDER CANCER OUTCOMES AND IMPACT STUDY Dominic Tang, Andrew Leone, Juan Chipollini, Paul Crispen, Carl Henriksen, Michael Poch, Wade Sexton, and Scott Gilbert Dominic TangDominic Tang More articles by this author , Andrew LeoneAndrew Leone More articles by this author , Juan ChipolliniJuan Chipollini More articles by this author , Paul CrispenPaul Crispen More articles by this author , Carl HenriksenCarl Henriksen More articles by this author , Michael PochMichael Poch More articles by this author , Wade SextonWade Sexton More articles by this author , and Scott GilbertScott Gilbert More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.2309AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Prior quality of life (QOL) research in bladder cancer has predominantly focused on differences between patients treated with radical cystectomy (RC) and different forms of urinary diversion. Other aspects of bladder cancer treatment, such as receipt of neoadjuvant chemotherapy (NAC), have gone unexamined. Using validated health questionnaires, we sought to determine the relationship between receipt of NAC and patient QOL. METHODS 124 patients were enrolled in a prospective complication and QOL assessment study between 2013 and 2015. Patients were surveyed longitudinally with a panel of health questionnaires, including the SF-36, a measure of general quality of life. The SF-36 contains 36 questions that assess several health domains, including physical functioning, physical health problems, pain, general health perception, emotional well-being, emotional health problems, social functioning and energy/fatigue. Patients surveyed in this study completed the SF-36 prior to cystectomy and at 3, 6 and 12-months following RC. Generalized linear models were used to examine differences in SF-36 scores by the primary exposure of interest (receipt of NAC) and adjusted for clinical and demographic factors. RESULTS 87 patients completed the SF-36 at both baseline and 6 months. The mean age was 68 years and 66 (75.8%) were men. More than half (46, 52.9%) received NAC. Patients who were not treated with NAC had lower SF-36 scores 6 months after RC (change in physical composite score (PCS) -1.47 vs. +1.95 and mental composite score (MCS) -1.96 vs. +3.68) compared to those who did. After adjusting for age, gender, diversion type and stage, receipt of NAC was significantly associated with higher general health perceptions (PE 5.29, p=0.012), emotional well-being (PE 5.41, p=0.012), and mental composite score (PE 6.02, p=0.005). There was no difference with NAC in PCS after controlling for confounders (p=0.10). CONCLUSIONS Receipt of NAC is a significant predictor of better quality of life 6 months after cystectomy as measured by SF-36. We found significant differences between patients treated with and without NAC in several domains, including mental composite score, general health perception, and emotional well-being. The exact mediators of this association need to be examined in larger studies. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e931 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Dominic Tang More articles by this author Andrew Leone More articles by this author Juan Chipollini More articles by this author Paul Crispen More articles by this author Carl Henriksen More articles by this author Michael Poch More articles by this author Wade Sexton More articles by this author Scott Gilbert More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...